MarketCap
Facebook
X
TelegramAnnual report 2021
added 12-23-2023
BioDelivery Sciences International DSO Ratio 2011-2025 | BDSI
Annual DSO Ratio BioDelivery Sciences International
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 115 | 101 | 85.9 | 73.7 | 36.6 | 83.8 | 18.8 | 29.4 | 89.8 | 3.49 | 11.3 |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 115 | 3.49 | 59 |
Quarterly DSO Ratio BioDelivery Sciences International
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | - | - | - | 123 | 111 | 107 | 99.5 | 106 | 115 | 99.6 | 112 | 117 | 119 | 121 | 69 | 87.8 | 102 | 90.9 | 64.6 | 71.8 | 92.4 | 18.3 | 75.9 | 91.2 | 65.1 | 90.9 | 7.05 | 184 | 131 | 19.7 | 113 | 157 | 20.6 | 13.1 | 64.2 | 85.1 | 92.2 | 93.2 | 2.39 | 25.3 | 2.92 | 1.72 | - | 3.46 | 240 | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 240 | 1.72 | 83.1 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Arbutus Biopharma Corporation
ABUS
|
31.5 | $ 4.78 | -0.31 % | $ 793 M |  Canada |
 |
Aclaris Therapeutics
ACRS
|
6.01 | $ 3.03 | -0.49 % | $ 234 M |  USA |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
20.6 | $ 1.15 | -1.71 % | $ 6.27 M |  China |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Ascendis Pharma A/S
ASND
|
132 | $ 209.39 | -1.61 % | $ 5 B |  Danmark |
 |
Aptevo Therapeutics
APVO
|
79 | $ 0.6 | -35.8 % | $ 166 K | USA |
 |
Alterity Therapeutics Limited
ATHE
|
16.2 K | $ 3.12 | 0.81 % | $ 7.51 B |  Australia |
 |
Athersys
ATHX
|
22.6 | - | 3.77 % | $ 22.4 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 0.22 | 24.46 % | $ 479 M |  Israel |
 |
Acasti Pharma
ACST
|
1.97 | - | 4.01 % | $ 150 M | Canada |
 |
Adaptimmune Therapeutics plc
ADAP
|
25 | - | -15.15 % | $ 60.3 M | Britain |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
62.6 | $ 27.09 | 1.04 % | $ 1.31 B | USA |
 |
BeiGene, Ltd.
BGNE
|
49.5 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Anika Therapeutics
ANIK
|
77.3 | $ 9.6 | 1.27 % | $ 141 M | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
6.09 | - | -9.72 % | $ 5.89 M | USA |
 |
Berkeley Lights
BLI
|
103 | - | -7.31 % | $ 87 M | USA |
 |
bluebird bio
BLUE
|
2.47 | - | - | $ 546 M | USA |
 |
Arena Pharmaceuticals
ARNA
|
946 | - | -6.81 % | $ 3.04 B | USA |
 |
Calithera Biosciences
CALA
|
28.8 | - | -10.95 % | $ 876 K | USA |
 |
Axon Enterprise
AXON
|
134 | $ 584.81 | -1.07 % | $ 44.3 B | USA |
 |
Ayala Pharmaceuticals
AYLA
|
61.7 | - | - | $ 7.46 M | Israel |
 |
Aytu BioScience
AYTU
|
150 | $ 2.44 | -3.56 % | $ 15.3 M | USA |
 |
Acorda Therapeutics
ACOR
|
48.3 | - | -24.86 % | $ 820 K | USA |
 |
Catalyst Biosciences
CBIO
|
3.24 | $ 12.33 | -0.29 % | $ 812 M | USA |
 |
Brickell Biotech
BBI
|
254 | - | -5.38 % | $ 6.06 M | USA |
 |
Celldex Therapeutics
CLDX
|
86.5 | $ 26.29 | -2.01 % | $ 1.69 M | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
169 | $ 11.07 | 2.45 % | $ 716 M | USA |